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The role of indomethacin in the regulation of extracellular matrix synthesis was studied in dermal fibroblast cultures. 
Indomethacin (10 PM) blocked totally the prostaglandin secretion and markedly increased the synthesis of collagen. In 
parallel, measurement of fibronectin, type I and type III procollagen mRNA levels showed a substantial increase under 
the action of indomethacin. On the other hand, indomethacin did not modify the mRNA levels of dermatan sulfate pro- 
teoglycan core protein. Measurement of collagen production estimated as the amount of collagenase digestible protein 
and by specific radioimmunoassay indicated a good correlation with the corresponding mRNA levels. These results sug- 
gest that indomethacin can regulate the extracellular matrix deposition at a transcriptional level. 
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1. INTRODUCTION 
It is generally accepted that metabolites of the 
arachidonic cascade play major roles in inflamma- 
tion, asthma and platelet functions. Pro- 
inflammatory effects have been attributed to 
several mediators of this system, among which 
prostaglandins formed via the cyclooxygenase 
pathway. Conversely, the effectiveness of 
nonsteroidal anti-inflammatory drugs (NSAIDs) is 
mainly due to inhibition of cyclooxygenase, 
preventing the transformation of arachidonic acid 
to the stable prostaglandins [l]. 
Indomethacin is certainly one of the most widely 
used NSAIDs. A number of reports has 
documented the effect of this drug on several 
aspects of inflammation: chemotaxis of monocytes 
and polymorphonuclear leukocytes, production of 
superoxide anions, cellular immune function, 
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destruction of joint tissue [2]. However, very few 
studies deal with the eventual action of in- 
domethacin on the matrix synthesis, which is 
known to undergo marked changes in several in- 
flammatory diseases. An increased synthesis of 
collagen in granuloma of rats treated with in- 
domethacin has been reported [3,4]. Similarly, the 
in vitro production of collagen was increased in 
callus tissue from rats after in vivo treatment with 
indomethacin [5]. However, others have observed 
an inhibition of collagen synthesis in rat 
granuloma after local injection of indomethacin 
El. 
Using indomethacin as a control to block pro- 
staglandin formation in studies on the in vitro ef- 
fect of interleukin 1, it has been previously 
observed that the drug enhanced collagen synthesis 
[7,8]. Therefore, we planned the present study to 
investigate the effect of indomethacin added to 
fibroblast cultures on the expression of collagens I 
and III, fibronectin and dermatan sulfate pro- 
teoglycan (DSPG) core protein. We conclude that 
the drug acts as a potent stimulator of both pro- 
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collagen and fibronectin mRNA levels whereas it 
does not affect mRNA amounts of DSPG core 
protein. These findings suggest a differential 
modulation of indomethacin on extracellular 
matrix deposition which could be due to inhibition 
of prostaglandin synthesis. 
2. MATERIALS AND METHODS 
2.1. Cell cultures 
Fibroblasts obtained from explants of human foreskin were 
grown in Dulbecco’s modification of Eagle’s minimum essential 
medium (DMEM) supplemented with 10% heat inactivated 
fetal calf serum (FCS), penicillin (100 IU/ml), streptomycin 
(100 pg/ml) and fungizone (2.5 pg/ml). 
2.2. Experimental procedure 
Cells were grown to confluency in 175 cm2 flasks and prein- 
cubated for 24 h in DMEM supplemented with 10% FCS and 
50 ag/ml ascorbic acid. Then the medium was replaced and 
fresh medium containing also 50 fig/ml ,&aminopropionitrile 
(,&APN) was added, with or without indomethacin (10pM). 
After a 24 h incubation, the medium was collected for radioim- 
munoassay of collagens and prostaglandin Ez, and the cells 
were harvested for RNA extraction. 
For estimation of total collagen production, the incubation 
was performed in 9.6 cm’ Petri dishes using the same protocol 
except that 2.5 &i/ml [3H]proline (CEA, France, 
30-40 Ci/mM) were added to the cultures. Each experiment 
was performed in triplicate. 
2.3. Radioimmunoassay of collagens type I and type III 
The amounts of both collagens were estimated in the culture 
medium according to the method of Magloire et al. [9], using 
specific antibodies against human type I and type III collagens. 
2.4. Assay of labelled collagen and non-collagenous protein 
The radioactive collagen secreted in the medium was assayed 
as collagenase-digestible protein [lo] and expressed as dpm/pg 
of cell protein, measured by the method of Hartree [ 111. The 
amount of non-collagenous protein was estimated from the 
radioactivity remaining after collagenase digestion. 
, 
2.5. Prostaglandin E2 assay 
PGEz was assayed in the culture medium by specific radioim- 
munoassay [12] with antiserum from Institut Pasteur Produc- 
tion (France). 
2.6. DNA probes 
The following probes were employed: pHCAL1 (131 for pro- 
collagen al(I), pHFS3 [14] for procollagen cul(III), pHFN 1151 
for fibronectin, and GP40 [16], specific for dermatan sulfate 
proteoglycan core protein. pRGAPDH [17], a probe specific 
for rat glyceraldehyde-3-phosphate d hydrogenase, was used as 
a control. 
2.7. RNA isolation and nucleic acid hybridization 
Total cellular RNA was extracted as described [18]. Briefly, 
cells were lysed in 5 M guanidine thiocyanate, RNA was selec- 
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tively precipitated with 4 M LiCl and extracted with phenol- 
chloroform. For Northern blots, 12tg RNA of each sample 
were denatured with glyoxal in duplicate and fractionated elec- 
trophoretically in a 0.75% agarose gel. One set of the samples 
was stained with ethidium bromide to visualize the 18 S and 
28 S rRNA subunits and check the preservation of RNA after 
extraction, the other set was transferred to Pall Biodyne A 
nylon membrane and immobilized by baking. Prehybridization 
was carried out as described by Thomas [19]. Hybridizations 
were performed in the prehybridization solution at 42°C for 
24 h using cDNA probes labelled by nick translation with 
[cr-“P]dCTP (800 Ci/mmol, Amersham, England) to a specific 
activity of about 5 x 10’ cpm/pg. After hybridization, filters 
were washed three times for 5 min in 2 x SSC/O.l% SDS at 
25’C and twice for 30 min in 0.1 x SSC/O.l% SDS at 55’C. 
Autoradiography was performed at -7O’C using Kodak X- 
Omat S films and scanned for quantitative determination of 
mRNA amount. The same filters were successively hybridized 
with the five probes. To remove the probes between hybridiza- 
tions, the filters were washed in 50% formamide/lO mM 
sodium phosphate, pH 6.5, for 1 h at 65°C followed by wash 
in 2 x SSC/O.l% SDS at 25°C for 15 min. 
3. RESULTS 
3.1. Effect of indomethacin on collagen and 
non-collagenous protein synthesis by 
confluent human dermal fibroblasts 
The concentration of 10 FM indomethacin was 
chosen after previous experiments showing that 
this drug level was required to completely inhibit 
the formation of prostaglandins in cultured dermal 
fibroblasts. The basal production of PGEz in our 
cultures, estimated in triplicate, was 3366 + 
780 pg/ml per 24 h. In the presence of 10 PM in- 
Table 1 
Total collagen and non-collagenous protein produced in the 
medium 
Collagen Non-collagenous 
protein 
dpm/pg % of dpm/Fg % of 
protein control protein control 
Control 266 f 73 100 1147f95 loo 
Indo 1OpM 419 i 92 158 1067 + 70 93 
Confluent cultures were preincubated for 24 h with SOcg/ml 
ascorbic acid in DMEM containing 10% FCS. Then the 
medium was discarded and fresh complete medium containing 
50 pg/ml ascorbic acid, 50 pg/ml ,&APN and 2.5 &i/ml 
13H]proline was added, with or without indomethacin. After a 
24 h incubation, the amounts of newly synthesized collagen and 
non-collagenous protein were estimated in the medium as 
described in section 2. Values are mean f SE of triplicate wells 
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Table 2 
Radioimmunoassay of types I and III collagens in supernatants of fibroblasts cultured 
with or without indomethacin 
TypeI Cwnagen type III Total (I + III) 
ng/ml % of ng/ml % of ng/ml % of 
control control control 
Control 674 rt 34 100 242 k 18 100 916 100 
Indo 1OpM 1007 * 28 149 281 e 13 116 1288 141 
April 1988 
Experimental conditions were the same as for table 1, without [“Hlproline. After 
incubation, the type I and type III collagens were estimated by radioimmunoassay. Values 
are mean f SE of duplicate flasks 
domethacin, this level was reduced to 92 k 
21 pg/ml per 24 h which represents practically 
2-3% of the control value. The effect on 
collagenase-digestible protein produced in such 
conditions is presented in table 1. Only culture 
medium was assayed since control experiments 
showed that more than 90% of the total collagen 
synthesized was recovered in the medium and that 
0 
lndo - + 
the relative distribution between cell layer and 
medium was not affected by indomethacin treat- 
ment (not shown). It was found that indomethacin 
increased the amount of radioactivity incorporated 
in the neo-synthesized collagen compared to con- 
trol cultures,. The effect of indomethacin on this 
parameter was very significant since the mean 
value was nearly 60% above the basal level. On the 
0 
4.6 
I$ 1 pro or1 (I) 
1.9 
1 pro-1 (III) 
2.3 
1 FW 
1 1.1 DSPG 
1 1 GA POH 
Fig.1. Measurement of the steady-state mRNA levels of pro al(I), pro (rl(III), fibronectin (FN), dermatan sulfate proteoglycan core 
protein (DSPG) and glyceraldehyde-3-phosphate d hydrogenase (GAPDH) in human dermal fibroblasts. An equal amount of total 
cellular RNA (12 kg/lane) was size-fractionated in 0.75% agarose gel, and either stained with ethidium bromide (A) or transferred 
to nylon membrane and hybridized to nick-translated cDNA probes (B). (C) The scannings of each fluorograph. Values are relative 
densitometric units. 
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other hand, the amount of non-collagenous pro- 
tein deduced from the radioactivity remaining 
after collagenase digestion of samples was not af- 
fected, suggesting that the effect of indomethacin 
was selective for collagen. 
3.2. Relative proportion of coIlagens type I and 
type III produced in the presence of 
indomethacin 
To further characterize the effects of in- 
domethacin on fibroblast collagen biosynthesis, 
the amounts of type I and type III collagens 
secreted in the medium over a 24 h period were 
determined by specific radioimmunoassay. As 
shown in table 2, indomethacin produced a clear- 
cut increase in the proportion of type I collagen 
whereas type III collagen level was elevated to a 
lesser extent. As a consequence of this effect, the 
relative proportion of collagens released in the 
medium was altered (070 of type III: 21.8 in 
indomethacin-treated cultures versus 26.4 in 
controls). 
3.3. Levels of mRNA for procollagens, 
fibronectin and DSPG core protein in 
fibrobiasts treated with indomethacin 
We further determined the amounts of mRNA 
corresponding to four major proteins of the 
fibroblast extracellular matrix, including type I 
and type III collagens, in order to detect an even- 
tual effect of indomethacin at the transcriptional 
level. Total RNA was isolated, size-fractionated by 
Northern blot and sequential hybridizations per- 
formed. The results presented in fig.1 show that 
the expression of GAPDH gene was unaffected by 
exposure to indomethacin and could serve as a 
control. In contrast, the mRNA level for type I 
procollagen increased substantially in response to 
indomethacin. The amount of type III procollagen 
mRNA was also elevated, albeit to a lesser extent. 
The steady-state leve1 of fibronectin mRNA was 
similarly increased after exposure to in- 
domethacin. The drug, however, did not affect 
DSPG core protein mRNA. 
4. DISCUSSION 
The results presented here demonstrate that in- 
domethacin is capable of stimulating the produc- 
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tion of type I and type III collagen by dermal 
fibroblasts in culture. Hybridization of total RNA 
isolated from control and indomethacin-treated 
cultures with cDNA probes for types I and III pro- 
collagens demonstrated that the drug induced a 
related increase in the steady-state levels of mRNA 
for these proteins. A similar increase was also 
observed for fibronectin mRNA level. These 
results suggest that the increase in collagen produc- 
tion under the effect of indomethacin is a result of 
the corresponding increase in the respective mRNA 
levels. For the moment, we do not know whether 
this effect is due to enhanced transcription or 
decreased degradation of these mRNAs. In- 
terestingly, it has been recently reported that addi- 
tion of exogenous PGEz to fibroblast cultures 
induced an inhibition of types I and III collagens 
and fibronectin production which paralleled a 
decrease in the steady-state levels of the corre- 
sponding mRNAs [20]. Our present observations 
corroborate this finding as far as the indomethacin 
blockade of prostaglandin production could sup- 
press an inhibitory effect of PGE2 on the transcrip- 
tional activity. However, it cannot be excluded 
that other cellular processes besides inhibition of 
prostaglandin synthesis may contribute to the 
stimulation of collagen and fibronectin produc- 
tion. An interference with the GTP binding pro- 
tein, for example, has been suggested as a 
mechanism by which NSAIDs could inhibit ag- 
gregation of human neutrophils [21]. The present 
study is consistent with most of the investigations 
dealing with the in vivo effect of indomethacin on 
collagen synthesis which concluded to a 
stimulatory action [3-51. These data concern both 
experimental granuloma and callus tissue from 
femoral fractures. Furthermore, the stimulatory 
effect has been also observed in vitro using frac- 
ture callus tissue from indomethacin-treated rats 
[5]. Therefore, it is likely that the stimulation of 
collagen synthesis produced in vivo by in- 
domethacin involves the cellular effect observed 
here on fibroblast cultures. 
Human skin fibroblasts in culture produce small 
proteoglycans but the major sulfated product is a 
small size dermatan sulfate proteoglycan [16]. Us- 
ing a cDNA probe specific for the core protein 
mRNA of this small DSPG, we have demonstrated 
in the present study that indomethacin did not af- 
fect the transcriptional activity for this protein. 
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This finding suggests that synthesis of the core pro- 
tein of DSPG is regulated by processes different 
from those of collagen and fibronectin synthesis. 
Since this small proteoglycan binds specifically to 
collagen and could be involved in the formation of 
collagen fibrils [22,23], the differential modulation 
exerted by indomethacin may lead to alteration of 
the extracellular matrix composition with impaired 
physical properties as a consequence. 
In conclusion, indomethacin has been identified 
as a NSAID capable of stimulating collagen and 
fibronectin transcripts levels, probably via inhibi- 
tion of prostaglandin synthesis. This effect may be 
a critical event of the matrix metabolism in pa- 
tients receiving indomethacin. 
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